Attached files

file filename
8-K - 8-K FILING - PRO DEX INCf17-0993.htm

 

Exhibit 99.1

Contact: Richard L. Van Kirk,

Chief Executive Officer

(949) 769-3200

For Immediate Release

 

PRO-DEX, INC. ANNOUNCES FISCAL 2017 SECOND QUARTER
AND SIX-MONTH RESULTS

 

IRVINE, CA, February 9, 2017 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2017 second quarter ended December 31, 2016. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2017 with the Securities and Exchange Commission today.

 

Sale of OMS Division

 

As recently disclosed in a Form 8-K and related press release, we sold our Oregon Micro Systems (“OMS”) division to the division’s long-time general manager on January 27, 2017. The gain on the sale of approximately $0.3 million will be recorded during our third quarter of fiscal 2017. As required by the accounting guidance, we have prepared the second quarter financial statements with the OMS division reflected as a discontinued operation, which impacts all periods presented in the accompanying financial statements below.

 

Quarter Ended December 31, 2016

 

Net sales for the three months ended December 31, 2016 decreased $632,000, or 12%, to $4.6 million from $5.2 million for the three months ended December 31, 2015, due to continued declining sales of our legacy dental products as well as reduced repair revenue.

 

Gross profit for the three months ended December 31, 2016 decreased $114,000, or 8%, to $1.3 million from $1.4 million for the same period in fiscal 2015. Although the gross profit declined during the three months ended December 31, 2016 compared to the corresponding period of the prior year, the gross margin percentage increased by 1 percentage point to 28% from 27%. The increase in margin is reflective of cost-cutting measures that were implemented during the quarter.

 

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended December 31, 2016 increased $103,000 or 11%, to $1.0 million compared to the prior fiscal year’s corresponding quarter, reflecting primarily increased legal expenses in support of ongoing litigation related to our former investment in real property located in Ramsey, Minnesota as described more fully in our Form 10-Q.

 

Income from continuing operations for the quarter ended December 31, 2016 increased by $2.7 million to $3.1 million, compared to $481,000 in the corresponding quarter in fiscal 2016. This increase reflects our income tax benefit of $2.9 million due to the release of our valuation allowance against our deferred tax assets because we have reassessed our valuation allowance and believe that it is more likely than not that we will generate sufficient levels of future profitability to realize substantially all of our deferred tax assets. Net income for the quarter ended December 31, 2016 was $3.2 million, or $0.78 per share, compared to $391,000, or $0.09 per share, for the corresponding quarter in fiscal 2016.

 

 

Six Months Ended December 31, 2015

 

Net sales for the six months ended December 31, 2016 increased $705,000, or 8%, to $9.7 million from $9.0 million for the six months ended December 31, 2015, due primarily to increases in medical device product revenues offset by reduced repair revenue and legacy dental product sales. We expect our repair revenue for the balance of fiscal 2017 to be lower than the comparable periods of the prior fiscal year because many of our products are relatively new and more repairs are covered under warranty than in the previous periods.

 

Gross profit for the six months ended December 31, 2016 increased $0.4 million, or 17% compared to the same period in fiscal 2016. The gross profit increase is due to increased net sales of 8% as well as improved margins due to our investment in machinery and equipment.

 

Operating expenses (which include selling, general and administrative, and research and development expenses) for the six months ended December 31, 2016 increased 14% to $2.2 million from $1.9 million in the prior fiscal year’s corresponding period, reflecting primarily increased general and administrative expenses mostly related to our ongoing litigation related to our former investment in real property located in Ramsey, Minnesota as well as increased research and development costs relating to internal projects.

 

Income from continuing operations for the six months ended December 31, 2016 was $3.4 million, compared to $408,000 for the corresponding period in fiscal 2016. This increase also reflects the tax benefit recorded in the second quarter due to the release of the valuation allowance against our deferred tax assets. Net income for the six months ended December 31, 2016 was $3.5 million or $0.85 per share, compared to $265,000, or $0.07 per share, for the corresponding period in fiscal 2016.

 

CEO Comments

 

Richard L. (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer, commented, “We are pleased with our second quarter and year-to-date results and we are pleased to have announced the sale of our OMS division. The capital infusion will be used for certain internal R&D efforts that we expect will further enhance our line of surgical drivers. We look forward to continuing our momentum this fiscal year.”

 

About Pro-Dex, Inc.:

 

Pro-Dex, Inc. specializes in the design, development and manufacture of powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets.  Its Fineline Molds division manufactures plastic injection molding for a variety of industries. Pro-Dex’s products are found in hospitals, dental offices, and medical engineering labs around the world.

 

Pro-Dex also provides quality and regulatory consulting services, as well as engineering consulting and placement services through its Engineering Services Division.  For more information, visit the Company’s website at www.pro-dex.com.

 

Statements herein concerning the Company’s plans, growth and strategies may include ‘forward-looking statements’ within the context of the federal securities laws. Statements regarding the Company’s future events, developments and future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company’s actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company’s filings with the Securities and Exchange Commission.

 

(tables follow)

 
 

 

PRO-DEX, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share amounts)

 

   December 31,
2016
  June 30,
2016
ASSETS          
Current Assets:          
Cash and cash equivalents   $2,180   $2,294 
         Investments    291    —   
Accounts receivable, net of allowance for doubtful accounts of $25 and $20, respectively    1,026    1,469 
Due from factor    2,409    1,419 
Deferred costs    582    238 
Assets held for sale    310    287 
Other current receivables    32    91 
Inventory    3,272    3,364 
Prepaid expenses    123    129 
Total current assets    10,225    9,291 
Equipment and leasehold improvements, net    1,458    1,222 
Deferred income taxes    2,837     
Goodwill    112    112 
Intangibles, net    331    451 
Other assets    71    71 
Total assets   $15,034   $11,147 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current Liabilities:          
Accounts payable   $761   $841 
Accrued expenses    1,446    1,076 
Deferred revenue    452    212 
Notes payable    26    26 
         Income taxes payable    3    1 
Capital lease obligations    31     
Total current liabilities    2,719    2,156 
Deferred rent, net of current portion    23    68 
Notes and capital leases payable, net of current portion    91    46 
Total non-current liabilities    114    114 
Total liabilities    2,833    2,270 
Shareholders’ equity:          
Common shares; no par value; 50,000,000 shares authorized; 4,040,169 and 4,052,987 shares issued and outstanding at December 31, 2016 and June 30, 2016, respectively    17,838    17,988 
Accumulated comprehensive loss    (6)    
Accumulated deficit    (5,631)   (9,111)
Total shareholders’ equity    12,201    8,877 
Total liabilities and shareholders’ equity   $15,034   $11,147 
           

 

 
 

 

PRO-DEX, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME

(Unaudited)

(In thousands, except per share amounts)

 

   Three Months Ended
December 31,
  Six Months Ended
December 31,
   2016  2015  2016  2015
Net sales   $4,599   $5,231   $9,728   $9,023 
Cost of sales    3,288    3,806    6,995    6,694 
Gross profit    1,311    1,425    2,733    2,329 
                     
Operating expenses:                    
Selling expenses    159    223    421    394 
General and administrative expenses    605    452    1,169    986 
Research and development costs    278    264    581    528 
Total operating expenses    1,042    939    2,171    1,908 
                     
Operating income    269    486    562    421 
Interest expense    (4)   (20)   (7)   (26)
Interest income    11    1    12     
Gain from disposal of equipment        14    3    14 
                     
Income from continuing operations before income taxes    276    481    570    409 
Income tax (expense) benefit    2,859        2,852    (1)
                     
Income from continuing operations    3,135    481    3,422    408 
Income (loss) from discontinued operations,
net of income taxes
   59    (90)   58    (143)
Net income   $3,194   $391   $3,480   $265 
Other comprehensive income (loss), net of tax:                    
Unrealized loss from marketable equity investments   (6)       (6)    
Comprehensive income   $3,188   $391   $3,474   $265 
                     
Basic net income per share:                    
Income from continuing operations   $0.77   $0.11   $0.84   $0.10 
Income (loss) from discontinued operations    0.02    (0.02)   0.01    (0.04)
Net income   $0.79   $0.09   $0.85   $0.06 
Diluted net income per share:                    
Income from continuing operations   $0.77   $0.11   $0.84   $0.10 
Income (loss) from discontinued operations    0.01    (0.02)   0.01    (0.04)
Net income   $0.78   $0.09   $0.85   $0.06 
                     
Weighted average common shares outstanding:                    
Basic    4,057    4,143    4,060    4,142 
Diluted    4,092    4,165    4,098    4,161 
Common shares outstanding    4,040    4,149    4,040    4,149 

 

 
 

 

PRO-DEX, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

   Six Months Ended
December 31,
   2016  2015
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income   $3,480   $265 
Adjustments to reconcile net income to net cash provided by (used in) operating activities:          
Depreciation and amortization    275    334 
Gain from disposal of equipment    (3)   (14)
Share-based compensation    2    2 
Impairment of intangible assets    113     
Deferred income tax benefit    (2,837)    
Bad debt expense (recovery)    5    (16)
Changes in operating assets and liabilities:          
Accounts receivable, due from factor and other current receivables    (493)   (383)
Deferred costs    (344)   745 
Assets held for sale    (23)    
Inventory    92    (171)
Prepaid expenses and other assets    6     
Accounts payable, accrued expenses and deferred rent    245    (778)
Deferred revenue    240    (312)
Income taxes payable    2     
Net cash provided by (used in) operating activities    760    (328)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of investments    (300)    
Purchases of equipment and leasehold improvements    (376)   (21)
Purchase of Investment in Ramsey property and related notes receivable        (86)
Proceeds from liquidation of Ramsey assets        277 
Proceeds from sale of equipment    3    14 
Increase in intangibles    (20)   (1)
Net cash provided by (used in) investing activities    (693)   183 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Purchase of common stock    (168)    
    Proceeds from Note Payable        500 
    Proceeds from exercise of options and ESPP contributions    16    21 
    Borrowings from Summit Loan    600    1,600 
    Repayments on Summit Loan    (600)   (1,600)
Principal payments on notes payable and capital lease    (29)   (20)
Net cash provided by (used in) financing activities    (181)   501 
           
Net increase (decrease) in cash and cash equivalents    (114)   356 
Cash and cash equivalents, beginning of period    2,294    697 
Cash and cash equivalents, end of period   $2,180   $1,053